<?xml version='1.0' encoding='utf-8'?>
<document id="15379382"><sentence text="Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction."><entity charOffset="52-68" id="DDI-PubMed.15379382.s1.e0" text="cyclophosphamide" /><entity charOffset="73-81" id="DDI-PubMed.15379382.s1.e1" text="thiotepa" /><pair ddi="false" e1="DDI-PubMed.15379382.s1.e0" e2="DDI-PubMed.15379382.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s1.e0" e2="DDI-PubMed.15379382.s1.e1" /></sentence><sentence text="Cyclophosphamide (CP) and thiotepa (TT) are frequently administered simultaneously in high-dose chemotherapy regimens"><entity charOffset="0-16" id="DDI-PubMed.15379382.s2.e0" text="Cyclophosphamide" /><entity charOffset="18-20" id="DDI-PubMed.15379382.s2.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.15379382.s2.e0" e2="DDI-PubMed.15379382.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s2.e0" e2="DDI-PubMed.15379382.s2.e1" /></sentence><sentence text=" The prodrug CP shows strong autoinduction resulting in increased formation of its activated metabolite 4-hydroxycyclophosphamide (4OHCP)"><entity charOffset="104-129" id="DDI-PubMed.15379382.s3.e0" text="4-hydroxycyclophosphamide" /><entity charOffset="131-136" id="DDI-PubMed.15379382.s3.e1" text="4OHCP" /><entity charOffset="13-17" id="DDI-PubMed.15379382.s3.e2" text="CP" /><entity charOffset="134-138" id="DDI-PubMed.15379382.s3.e3" text="CP" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e2" e2="DDI-PubMed.15379382.s3.e2" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e2" e2="DDI-PubMed.15379382.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e2" e2="DDI-PubMed.15379382.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e2" e2="DDI-PubMed.15379382.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e0" e2="DDI-PubMed.15379382.s3.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e0" e2="DDI-PubMed.15379382.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e0" e2="DDI-PubMed.15379382.s3.e3" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e1" e2="DDI-PubMed.15379382.s3.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s3.e1" e2="DDI-PubMed.15379382.s3.e3" /></sentence><sentence text=" TT inhibits this bioactivation of CP"><entity charOffset="35-36" id="DDI-PubMed.15379382.s4.e0" text="CP" /></sentence><sentence text=" Previously, we successfully modelled CP bioactivation and the effect of TT on the autoinduction"><entity charOffset="38-39" id="DDI-PubMed.15379382.s5.e0" text="CP" /></sentence><sentence text=" Recently we suggested that CP may also induce the conversion of TT in to its metabolite tepa (T)"><entity charOffset="28-29" id="DDI-PubMed.15379382.s6.e0" text="CP" /></sentence><sentence text=" The aim of the current study was to investigate whether the influence of CP on TT metabolism can be described with a population pharmacokinetic model and whether this interaction can be incorporated in an integrated model describing both CP and TT pharmacokinetics"><entity charOffset="74-75" id="DDI-PubMed.15379382.s7.e0" text="CP" /><entity charOffset="239-240" id="DDI-PubMed.15379382.s7.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.15379382.s7.e0" e2="DDI-PubMed.15379382.s7.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s7.e0" e2="DDI-PubMed.15379382.s7.e1" /></sentence><sentence text="" /><sentence text="Plasma samples were collected from 49 patients receiving 86 courses of a combination of high-dose CP (4000 or 6000 mg/m2), TT (320 or 480 mg/m2) and carboplatin (1067 or 1600 mg/m2) given in short infusions during four consecutive days"><entity charOffset="149-160" id="DDI-PubMed.15379382.s9.e0" text="carboplatin" /><entity charOffset="98-108" id="DDI-PubMed.15379382.s9.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.15379382.s9.e1" e2="DDI-PubMed.15379382.s9.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s9.e1" e2="DDI-PubMed.15379382.s9.e0" /></sentence><sentence text=" For each patient, approximately 20 plasma samples were available per course" /><sentence text=" Concentrations of CP, 4OHCP, TT and T were determined using GC and HPLC"><entity charOffset="19-20" id="DDI-PubMed.15379382.s11.e0" text="CP" /><entity charOffset="26-27" id="DDI-PubMed.15379382.s11.e1" text="CP" /><entity charOffset="23-24" id="DDI-PubMed.15379382.s11.e2" text="4OHCP" /><pair ddi="false" e1="DDI-PubMed.15379382.s11.e0" e2="DDI-PubMed.15379382.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s11.e0" e2="DDI-PubMed.15379382.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15379382.s11.e0" e2="DDI-PubMed.15379382.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s11.e2" e2="DDI-PubMed.15379382.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15379382.s11.e2" e2="DDI-PubMed.15379382.s11.e1" /></sentence><sentence text=" Kinetic data were processed using NONMEM" /><sentence text="" /><sentence text="The pharmacokinetics of TT and T were described with a two-compartment model" /><sentence text=" TT was eliminated through a non-inducible and an inducible pathway, the latter resulting information of T (ClindTT = 12" /><sentence text="4 l/hr, ClnonindTT = 17" /><sentence text="0 l/hr)" /><sentence text=" Induction of TT metabolism was mediated by a hypothetical amount of enzyme, different from that involved in CP induction, whose amount increased with time in the presence of CP"><entity charOffset="109-113" id="DDI-PubMed.15379382.s18.e0" text="CP" /><entity charOffset="175-179" id="DDI-PubMed.15379382.s18.e1" text="CP" /><pair ddi="false" e1="DDI-PubMed.15379382.s18.e0" e2="DDI-PubMed.15379382.s18.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s18.e0" e2="DDI-PubMed.15379382.s18.e1" /></sentence><sentence text=" The amount of enzyme followed a zero-order formation and a decrease with a first-order elimination rate constant of 0" /><sentence text="0343 hr(-1) (t1/2 = 20 hr)" /><sentence text=" This model was significantly better than a model lacking the induction by CP"><entity charOffset="75-76" id="DDI-PubMed.15379382.s21.e0" text="CP" /></sentence><sentence text=" The model was successfully incorporated into the previously published pharmacokinetic model for CP, and resulted in comparable parameter estimates for this compound and its metabolite 4OHCP"><entity charOffset="97-98" id="DDI-PubMed.15379382.s22.e0" text="CP" /><entity charOffset="188-189" id="DDI-PubMed.15379382.s22.e1" text="CP" /><entity charOffset="185-186" id="DDI-PubMed.15379382.s22.e2" text="4OHCP" /><pair ddi="false" e1="DDI-PubMed.15379382.s22.e0" e2="DDI-PubMed.15379382.s22.e0" /><pair ddi="false" e1="DDI-PubMed.15379382.s22.e0" e2="DDI-PubMed.15379382.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15379382.s22.e0" e2="DDI-PubMed.15379382.s22.e1" /><pair ddi="false" e1="DDI-PubMed.15379382.s22.e2" e2="DDI-PubMed.15379382.s22.e2" /><pair ddi="false" e1="DDI-PubMed.15379382.s22.e2" e2="DDI-PubMed.15379382.s22.e1" /></sentence><sentence text="" /><sentence text="The pharmacokinetics of TT, when administered in combination with CP, were successfully described"><entity charOffset="66-70" id="DDI-PubMed.15379382.s24.e0" text="CP" /></sentence><sentence text=" The model confirms induction of TT metabolism with time and it appears likely that CP is responsible for this phenomenon"><entity charOffset="84-85" id="DDI-PubMed.15379382.s25.e0" text="CP" /></sentence><sentence text=" The existence of a mutual pharmacokinetic interaction between CP and TT, as described in our integrated model, may be relevant in clinical practice"><entity charOffset="63-64" id="DDI-PubMed.15379382.s26.e0" text="CP" /></sentence><sentence text="" /></document>